ArticleHealth science reports2026
The Efficacy of Combination Therapy With SWTX Capsule and Paroxetine for Depression: A Randomized Controlled Trial.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Efficacy of Combination Therapy With SWTX Capsule and Paroxetine for Depression: A Randomized Controlled Trial.Health science reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Depression, a leading global cause of disease burden, often shows limited response and notable adverse reactions to existing antidepressants. Exploring combination therapies is therefore crucial to enhance therapeutic efficacy and improve safety. Consequently, this study aimed to explore the alterations in blood concentration, therapeutic effect, and safety of San Wei Tan Xiang (SWTX) capsule in combination with paroxetine for the treatment of patients suffering from depression. Methods: Seventy-six patients fulfilling the diagnostic criteria for depression were enrolled in this randomized controlled trial and randomly divided into a Combination Therapy Group (paroxetine plus SWTX capsule) and a Monotherapy Group (paroxetine alone). Paroxetine blood concentrations and the Treatment Emergent Symptom Scale (TESS) were measured at the second, fourth, and eighth weeks. The 24-item Hamilton Depression Rating Scale (HAMD-24) and the Montgomery Asberg Depression Rating Scale (MADRS) assessed depressive symptoms at baseline and the second, fourth, and eighth weeks. Results: In the eighth week, the blood paroxetine concentration in the Monotherapy Group was markedly elevated compared to the Combination Therapy Group ( Conclusion: Combining SWTX capsule with paroxetine might help maintain paroxetine blood concentration within the optimal range of 20-65 ng/mL, which could potentially lead to better alleviation of depressive symptoms and may reduce adverse reactions compared to paroxetine monotherapy, possibly enhancing overall treatment safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.